Main > > >ASPIRIN. *

Cardio.>Aspirin. MI Prevention? Compa- nion DIAG.:
11-DeHydro Thromboxane B2 ELISA Urine
Test.
USA Approval Date: 2007. 05.29.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.18.




Cardio.>Aspirin+OmeprAzole Delayed Release Tablets.
Indications:
Aspirin Component:
. Reducing the combined risk of death
and nonfatal MI in patients with a
previous MI or unstable angina
pectoris
. Reducing the combined risk of MI and
sudden death in patients with chronic
stable angina pectoris
. Use in patients who have undergone
revascularization procedures (Coronary
Artery Bypass Graft [CABG] or
Percutaneous Transluminal Coronary
Angioplasty [PTCA]) when there is a
pre-existing condition for which
aspirin is already indicated
OmeprAzole Component:
. decreasing the risk of developing
aspirin-associated gastric ulcers in
patients at risk for developing
aspirin-associated gastric ulcers due
to age (≥ 55) or documented history of
gastric ulcers.
USA Approval Date: 2016. 09.15.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2019. 03.18.




>ASPIRIN. *'s products
This section has no products